The cellular thermal shift assay for evaluating drug target interactions in cells

Martinez Molina, D. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84–87 (2013).

Brandts, J.F. & Lin, L.N. Study of strong to ultratight protein interactions using differential scanning calorimetry. Biochemistry 29, 6927–6940 (1990).

Crothers, D.M. Statistical thermodynamics of nucleic acid melting transitions with coupled binding equilibria. Biopolymers 10, 2147–2160 (1971).

Schellman, J.A. Macromolecular binding. Biopolymers 14, 999–1018 (1975).

Matulis, D., Kranz, J.K., Salemme, F.R. & Todd, M.J. Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor. Biochemistry 44, 5258–5266 (2005).

Ericsson, U.B., Hallberg, B.M., Detitta, G.T., Dekker, N. & Nordlund, P. ThermoFluor-based high-throughput stability optimization of proteins for structural studies. Anal. Biochem. 357, 289–298 (2006).

Niesen, F.H., Berglund, H. & Vedadi, M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2, 2212–2221 (2007).

Pantoliano, M.W. et al. High-density miniaturized thermal shift assays as a general strategy for drug discovery. J. Biomol. Screen. 6, 429–440 (2001).

Senisterra, G.A. et al. Screening for ligands using a generic and high-throughput light-scattering-based assay. J. Biomol. Screen. 11, 940–948 (2006).

Fedorov, O. et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl. Acad. Sci. USA 104, 20523–20528 (2007).

Vedadi, M. et al. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc. Natl. Acad. Sci. USA 103, 15835–15840 (2006).

Garnett, M.J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570–575 (2012).

Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).

Feng, B.Y. & Shoichet, B.K. A detergent-based assay for the detection of promiscuous inhibitors. Nat. Protoc. 1, 550–553 (2006).

Walters, W.P. & Namchuk, M. Designing screens: how to make your hits a hit. Nat. Rev. Drug Disc. 2, 259–266 (2003).

Nordlund, P. Methods for determining ligand binding to a target protein using a thermal shift assay. UK patent no. GB2490404 (2012).

Weibrecht, I. et al. Proximity ligation assays: a recent addition to the proteomics toolbox. Exp. Rev. Proteom. 7, 401–409 (2010).

Knaust, R.K. & Nordlund, P. Screening for soluble expression of recombinant proteins in a 96-well format. Anal. Biochem. 297, 79–85 (2001).

Asial, I. et al. Engineering protein thermostability using a generic activity-independent biophysical screen inside the cell. Nat. Commun. 4, 2901 (2013).

Branca, R.M et al. HiRIEF LC-MS enables deep proteome coverage and unbiased proteogenomics. Nat. Methods 11, 59–62 (2014).

Eglen, R.M. et al. The use of AlphaScreen technology in HTS: current status. Curr. Chem. Genomics 1, 2–10 (2008).

Bazin, H., Preaudat, M., Trinquet, E. & Mathis, G. Homogeneous time resolved fluorescence resonance energy transfer using rare earth cryptates as a tool for probing molecular interactions in biology. Spectrochim. Acta. A Mol. Biomol. Spectrosc. 57, 2197–2211 (2001).

Osmond, R.I.W., Das, S. & Crouch, M.F. Development of cell-based assays for cytokine receptor signaling, using an AlphaScreen SureFire assay format. Anal. Biochem. 403, 94–9101 (2010).

Bembenek, M.E. et al. Determination of complementary antibody pairs using protein A capture with the AlphaScreen assay format. Anal. Biochem. 408, 321–327 (2011).

Copeland, R.A., Pompliano, D.L. & Meek, T.D. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Disc. 5, 730–739 (2006).

Lepock, J.R. et al. Influence of transition rates and scan rate on kinetic simulations of differential scanning calorimetry profiles of reversible and irreversible protein denaturation. Biochemistry 31, 12706–12712 (1992).

Quistgaard, E.M. et al. Structural and biophysical characterization of the cytoplasmic domains of human BAP29 and BAP31. PLoS ONE 8, e71111 (2013).

Saklatvala, J. et al. Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue. J. Biol. Chem. 271, 6586–6589 (1996).

Dominguez, C., Powers, D.A. & Tamayo, N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr. Opin. Drug Disc. Dev. 8, 421–430 (2005).

Aronov, A.M. et al. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. J. Med. Chem. 52, 6362–6368 (2009).

Zhang, J.H., Chung, T.D. & Oldenburg, K.R. A simple statistical parameter for use in evaluation and validation of high-throughput screening assays. J. Biomol. Screen. 4, 67–73 (1999).

Richman, D.D., Cleveland, P.H., Oxman, M.N. & Johnson, K.M. The binding of staphylococcal protein A by the sera of different animal species. J. Immunol. 128, 2300–2305 (1982).